	US 11,865,102 B2
	Cannabidiol preparations and its uses
Geoffrey Guy, Cambridge (GB); Volker Knappertz, Cambridge (GB); Benjamin Whalley, Cambridge (GB); Marie Woolley-Roberts, Cambridge (GB); James Brodie, Cambridge (GB); Katarzyna Lach-Falcone, Cambridge (GB); Alan Sutton, Cambridge (GB); Royston Gray, Cambridge (GB); and Rohini Rajyalaxmi Rana, Cambridge (GB)
Assigned to GW Research Limited, Cambridge (GB)
Filed by GW Research Limited, Cambridge (GB)
Filed on Nov. 17, 2021, as Appl. No. 17/529,005.
Application 17/529,005 is a continuation of application No. 17/011,715, filed on Sep. 3, 2020, granted, now 11,207,292.
Application 17/011,715 is a continuation of application No. PCT/GB2019/051173, filed on Apr. 26, 2019.
Claims priority of application No. 1806953 (GB), filed on Apr. 27, 2018.
Prior Publication US 2022/0168266 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61P 25/08 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/05 (2006.01); A61K 36/185 (2006.01); A61P 25/18 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0073 (2013.01); A61K 9/7023 (2013.01); A61K 31/05 (2013.01); A61K 36/185 (2013.01); A61P 25/08 (2018.01); A61P 25/18 (2018.01); A61K 2236/33 (2013.01); A61K 2236/51 (2013.01)]

30 Claims

1. A cannabidiol (CBD) preparation comprising greater than or equal to 90% (w/w) CBD based on total amount of cannabinoid in the preparation and the remainder comprises other cannabinoids, wherein the other cannabinoids comprise tetrahydrocannabinol (THC), wherein the THC is present as a mixture of trans-THC and cis-THC, and wherein the ratio of trans-THC to cis-THC is about 0.7:1.0 to about 5.0:1.0.